Related Experiment Video
Updated: May 19, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Are there still healthy obese patients?
1Department of Medicine, University of Leipzig, Germany. bluma@medizin.uni-leipzig.de
Current Opinion in Endocrinology, Diabetes, and Obesity
|August 17, 2012
Summary
A subset of obese individuals, up to 30%, are metabolically healthy, showing protection against obesity-related comorbidities. Understanding these healthy obesity mechanisms is key for targeted interventions.
Area of Science:
- Metabolic Health
- Obesity Research
- Cardiovascular Health
Background:
- Obesity is a global epidemic linked to premature death and increased risk of metabolic disorders, hypertension, heart disease, stroke, and cancer.
- A distinct subgroup of obese individuals, termed 'healthy' obese, appears protected from obesity-related comorbidities.
- This review explores the underlying mechanisms contributing to this healthy obese subphenotype.
Purpose of the Study:
- To investigate the potential mechanisms responsible for the 'healthy obese' phenotype.
- To differentiate between metabolically healthy and unhealthy obese individuals.
- To inform stratified approaches to obesity treatment.
Main Methods:
- Review of recent studies on obesity and metabolic health.
- Analysis of factors contributing to protection against metabolic and cardiovascular comorbidities in obese individuals.
- Identification of key differences between metabolically healthy and unhealthy obese phenotypes.
Main Results:
- Up to 30% of individuals with obesity are metabolically healthy, exhibiting insulin sensitivity comparable to lean individuals.
- These individuals often have lower liver fat content and reduced carotid artery intima-media thickness compared to metabolically unhealthy obese counterparts.
- Protection against hepatic steatosis, ectopic fat deposition, visceral adipose tissue inflammation, and adipose tissue dysfunction are suggested mechanisms for healthy obesity.
Conclusions:
- Defining metabolically healthy versus high-risk obese phenotypes is crucial for stratifying obesity treatment.
- This stratification will aid in identifying individuals who would most benefit from early interventions such as lifestyle changes, bariatric surgery, or pharmacotherapy.
Related Concept Videos
Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Stress Prevention and Stress Management Techniques IV
Stress often leads to unhealthy habits like smoking, excessive drinking, and overeating, which offer short-term relief but ultimately increase long-term health risks. These behaviors create a cycle that temporarily lowers stress levels but can result in severe long-term health consequences. Breaking these habits is essential to reduce the risk of chronic diseases and improve overall well-being. Three primary changes that support better health include quitting smoking, reducing alcohol intake,...

